{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:15:45Z","timestamp":1793247345735,"version":"4.5.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00210-025-04268-8","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T05:28:05Z","timestamp":1747459685000},"page":"14617-14635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Advancing fungal keratitis treatment: transitioning from conventional amphotericin B therapy to nanocarrier-based delivery systems"],"prefix":"10.1007","volume":"398","author":[{"given":"Gourav","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aians H.","family":"Kalita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jabin","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhi","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astha","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balak","family":"Das Kurmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghanshyam","family":"Das Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5857-2624","authenticated-orcid":false,"given":"Shubham","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"4268_CR1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jconrel.2023.08.018","volume":"362","author":"KK Abla","year":"2023","unstructured":"Abla KK, Mehanna MM (2023) Lipid-based nanocarriers challenging the ocular biological barriers: current paradigm and future perspectives. J Control Release 362:70\u201396","journal-title":"J Control Release"},{"issue":"2","key":"4268_CR2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1208\/s12249-023-02516-9","volume":"24","author":"S Ahmed","year":"2023","unstructured":"Ahmed S, Amin MM, Sayed S (2023) Ocular drug delivery: a comprehensive review. AAPS PharmSciTech 24(2):66","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"4268_CR3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/gels8020082","volume":"8","author":"MH Akhter","year":"2022","unstructured":"Akhter MH et al (2022) Drug delivery challenges and current progress in nanocarrier-based ocular therapeutic system. Gels 8(2):82","journal-title":"Gels"},{"key":"4268_CR4","unstructured":"Amphotericin B topical: action, formulation, and resistance (n.d.) [cited 2025; Available from: https:\/\/biologyinsights.com\/amphotericin-b-topical-action-formulation-and-resistance\/. Accessed 24 Dec 2024"},{"key":"4268_CR5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2023045298","volume":"41","author":"M Ansari","year":"2024","unstructured":"Ansari M, Kulkarni YA, Singh K (2024) Advanced technologies of drug delivery to the posterior eye segment targeting angiogenesis and ocular cancer. Crit Rev\u2122 Ther Drug Carrier Syst 41:85\u2013124","journal-title":"Crit Rev\u2122 Ther Drug Carrier Syst"},{"issue":"2","key":"4268_CR6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/AAC.13.2.271","volume":"13","author":"AJ Atkinson Jr","year":"1978","unstructured":"Atkinson AJ Jr, Bennett JE (1978) Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 13(2):271\u2013276","journal-title":"Antimicrob Agents Chemother"},{"key":"4268_CR7","unstructured":"Available from (n.d.) https:\/\/toolkit.ncats.nih.gov\/glossary\/inclusion-criteria\/#:~:text=In%20a%20clinical%20study%2C%20inclusion,allowed%20to%20participate%20in%20a. Accessed 24 Dec 2024"},{"key":"4268_CR8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2147\/OPTH.S447138","volume":"18","author":"R Awad","year":"2024","unstructured":"Awad R et al (2024) Fungal keratitis: diagnosis, management, and recent advances. Clin Ophthalmol 18:85\u2013106","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"4268_CR9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/pharmaceutics10010028","volume":"10","author":"RD Bachu","year":"2018","unstructured":"Bachu RD et al (2018) Ocular drug delivery barriers\u2014role of nanocarriers in the treatment of anterior segment ocular diseases. Pharmaceutics 10(1):28","journal-title":"Pharmaceutics"},{"issue":"1","key":"4268_CR10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1248\/cpb.c22-00534","volume":"71","author":"K Banshoya","year":"2023","unstructured":"Banshoya K et al (2023) A novel amphotericin b hydrogel composed of poly (Vinyl Alcohol)\/borate complex for ophthalmic formulation. Chem Pharm Bull 71(1):70\u201373","journal-title":"Chem Pharm Bull"},{"issue":"6","key":"4268_CR11","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.molmed.2021.04.002","volume":"27","author":"CJ Batty","year":"2021","unstructured":"Batty CJ, Bachelder EM, Ainslie KM (2021) Historical perspective of clinical nano and microparticle formulations for delivery of therapeutics. Trends Mol Med 27(6):516\u2013519","journal-title":"Trends Mol Med"},{"issue":"06","key":"4268_CR12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1055\/s-0035-1546032","volume":"232","author":"W Behrens-Baumann","year":"2015","unstructured":"Behrens-Baumann W et al (2015) Keratomykose-Therapiestandards und aktuelle Entwicklungen. Klin Monbl Augenheilkd 232(06):754\u2013764","journal-title":"Klin Monbl Augenheilkd"},{"key":"4268_CR13","doi-asserted-by":"crossref","first-page":"108372","DOI":"10.1016\/j.exer.2020.108372","volume":"202","author":"M Bethany","year":"2021","unstructured":"Bethany M et al (2021) The role of fungi in fungal keratitis. Exp Eye Res 202:108372","journal-title":"Exp Eye Res"},{"issue":"2","key":"4268_CR14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.7164\/antibiotics.28.132","volume":"28","author":"D Bonner","year":"1975","unstructured":"Bonner D, Mechlinski W, Schaffner CP (1975) Stability studies with amphotericin B and amphotericin B methyl ester. J Antibiot 28(2):132\u2013135","journal-title":"J Antibiot"},{"issue":"9","key":"4268_CR15","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.1016\/S2214-109X(17)30293-0","volume":"5","author":"RR Bourne","year":"2017","unstructured":"Bourne RR et al (2017) Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. Lancet Glob Health 5(9):e888\u2013e897","journal-title":"Lancet Glob Health"},{"issue":"4","key":"4268_CR16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","volume":"35","author":"R Bowden","year":"2002","unstructured":"Bowden R et al (2002) A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 35(4):359\u2013366","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4268_CR17","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/S1473-3099(20)30448-5","volume":"21","author":"L Brown","year":"2021","unstructured":"Brown L et al (2021) The global incidence and diagnosis of fungal keratitis. Lancet Infect Dis 21(3):e49\u2013e57","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"4268_CR18","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1167\/iovs.02-1020","volume":"44","author":"JP Cannon","year":"2003","unstructured":"Cannon JP et al (2003) Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. Invest Ophthalmol vis Sci 44(5):2112\u20132117","journal-title":"Invest Ophthalmol vis Sci"},{"issue":"06","key":"4268_CR19","first-page":"0914","volume":"2006","author":"DM Cereghetti","year":"2006","unstructured":"Cereghetti DM, Carreira EM (2006) Amphotericin B: 50 years of chemistry and biochemistry. Synthesis 2006(06):0914\u20130942","journal-title":"Synthesis"},{"issue":"5","key":"4268_CR20","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0006-2952(88)90168-2","volume":"37","author":"M Ch\u00e9ron","year":"1988","unstructured":"Ch\u00e9ron M et al (1988) Quantitative structure-activity relationships in amphotericin B derivatives. Biochem Pharmacol 37(5):827\u2013836","journal-title":"Biochem Pharmacol"},{"issue":"1\u20132","key":"4268_CR21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0378-5173(97)00417-1","volume":"162","author":"B Cohen","year":"1998","unstructured":"Cohen B (1998) Amphotericin B toxicity and lethality: a tale of two channels. Int J Pharm 162(1\u20132):95\u2013106","journal-title":"Int J Pharm"},{"key":"4268_CR22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1378\/chest.54.Supplement_1.296","volume":"54","author":"JD Dutcher","year":"1968","unstructured":"Dutcher JD (1968) The discovery and development of amphotericin B. Dis Chest 54:296\u2013298","journal-title":"Dis Chest"},{"issue":"9","key":"4268_CR23","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3390\/pharmaceutics14091823","volume":"14","author":"S Fairuz","year":"2022","unstructured":"Fairuz S, Nair RS, Billa N (2022) Orally administered amphotericin B nanoformulations: physical properties of nanoparticle carriers on bioavailability and clinical relevance. Pharmaceutics 14(9):1823","journal-title":"Pharmaceutics"},{"issue":"3","key":"4268_CR24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/08982104.2016.1224899","volume":"27","author":"T Fu","year":"2017","unstructured":"Fu T et al (2017) Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy. J Liposome Res 27(3):228\u2013233","journal-title":"J Liposome Res"},{"issue":"30","key":"4268_CR25","first-page":"21","volume":"12","author":"P Garg","year":"1999","unstructured":"Garg P, Rao GN (1999) Corneal ulcer: diagnosis and management. Community Eye Health 12(30):21","journal-title":"Community Eye Health"},{"issue":"3","key":"4268_CR26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1167\/tvst.8.3.35","volume":"8","author":"AK Ghosh","year":"2019","unstructured":"Ghosh AK et al (2019) Evaluation of liposomal and conventional amphotericin B in experimental fungal keratitis rabbit model. Transl Vis Sci Technol 8(3):35\u201335","journal-title":"Transl Vis Sci Technol"},{"key":"4268_CR27","doi-asserted-by":"crossref","first-page":"130525","DOI":"10.1016\/j.ijbiomac.2024.130525","volume":"264","author":"J Gong","year":"2024","unstructured":"Gong J et al (2024) A review of recent advances of cellulose-based intelligent-responsive hydrogels as vehicles for controllable drug delivery system. Int J Biol Macromol 264:130525","journal-title":"Int J Biol Macromol"},{"key":"4268_CR28","doi-asserted-by":"crossref","first-page":"27835","DOI":"10.1039\/D0RA04971A","volume":"10","author":"S Gorantla","year":"2020","unstructured":"Gorantla S, Rapalli VK, Waghule T, Singh PP, Dubey SK, Sahaac RN, Singhvi G (2020) Nanocarriers for ocular drug delivery: current status and translational opportunity. RSC Adv 10:27835\u201327855","journal-title":"RSC Adv"},{"issue":"1","key":"4268_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7243\/2054-3425-6-1","volume":"6","author":"MBG Guajardo","year":"2018","unstructured":"Guajardo MBG et al (2018) Subconjunctivally injected liposome encapsulated sirolimus and topical tacrolimus for the treatment of non-responsive keratoconjunctivitis sicca in the spontaneous dog model. Vet Med Anim Sci 6(1):1","journal-title":"Vet Med Anim Sci"},{"key":"4268_CR30","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","volume":"73","author":"RJ Hamill","year":"2013","unstructured":"Hamill RJ (2013) Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 73:919\u2013934","journal-title":"Drugs"},{"key":"4268_CR31","first-page":"3436415","volume":"2016","author":"J Hu","year":"2016","unstructured":"Hu J et al (2016) A combination of intrastromal and intracameral injections of amphotericin B in the treatment of severe fungal keratitis. J Ophthalmol 2016:3436415","journal-title":"J Ophthalmol"},{"issue":"3","key":"4268_CR32","first-page":"309","volume":"91","author":"S Isipradit","year":"2008","unstructured":"Isipradit S (2008) Efficacy of fluconazole subconjunctival injection as adjunctive therapy for severe recalcitrant fungal corneal ulcer. Med J Med Assoc Thailand 91(3):309","journal-title":"Med J Med Assoc Thailand"},{"issue":"10","key":"4268_CR33","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/03639045.2018.1492606","volume":"44","author":"P Jansook","year":"2018","unstructured":"Jansook P, Pichayakorn W, Ritthidej GC (2018) Amphotericin B-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): effect of drug loading and biopharmaceutical characterizations. Drug Dev Ind Pharm 44(10):1693\u20131700","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"4268_CR34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-137-2-200207160-00008","volume":"137","author":"PC Johnson","year":"2002","unstructured":"Johnson PC et al (2002) Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 137(2):105\u2013109","journal-title":"Ann Intern Med"},{"issue":"12","key":"4268_CR35","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1080\/17425247.2024.2420750","volume":"21","author":"V Kailasam","year":"2024","unstructured":"Kailasam V, Sai Veda Koduganti S, Dasgupta O, Garg P, Nirmal J (2024a) Ocular delivery of Amphotericin B: current challenges and future perspectives. Exp Opin Drug Deliv 21(12):1793\u20131805","journal-title":"Exp Opin Drug Deliv"},{"issue":"12","key":"4268_CR36","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1080\/17425247.2024.2420750","volume":"21","author":"V Kailasam","year":"2024","unstructured":"Kailasam V et al (2024b) Ocular delivery of amphotericin B: current challenges and future perspectives. Expert Opin Drug Deliv 21(12):1793\u20131805","journal-title":"Expert Opin Drug Deliv"},{"key":"4268_CR37","unstructured":"Karunarathna I et al (2024a) Amphotericin B: a comprehensive overview of its clinical applications and toxicity management. ResearchGate. https:\/\/www.researchgate.net\/publication\/383276006. Accessed 24 Dec 2024"},{"key":"4268_CR38","unstructured":"Karunarathna I et al (2024b) The role of amphotericin B in modern antifungal therapy: indications, mechanisms, and adverse effects. ResearchGate. Available at https:\/\/www.researchgate.net\/publication\/383272573"},{"key":"4268_CR39","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.2147\/IJN.S190502","volume":"14","author":"A Khames","year":"2019","unstructured":"Khames A et al (2019) Natamycin solid lipid nanoparticles\u2013sustained ocular delivery system of higher corneal penetration against deep fungal keratitis: preparation and optimization. Int J Nanomed 14:2515\u20132531","journal-title":"Int J Nanomed"},{"issue":"7","key":"4268_CR40","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1049\/iet-nbt.2017.0003","volume":"11","author":"M Lachmapure","year":"2017","unstructured":"Lachmapure M et al (2017) Efficacy of biogenic silver nanoparticles against clinical isolates of fungi causing mycotic keratitis in humans. IET Nanobiotechnol 11(7):809\u2013814","journal-title":"IET Nanobiotechnol"},{"key":"4268_CR41","doi-asserted-by":"crossref","first-page":"118771","DOI":"10.1016\/j.ijpharm.2019.118771","volume":"572","author":"P Lakhani","year":"2019","unstructured":"Lakhani P et al (2019) Optimization, stabilization, and characterization of amphotericin B loaded nanostructured lipid carriers for ocular drug delivery. Int J Pharm 572:118771","journal-title":"Int J Pharm"},{"key":"4268_CR42","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.micpath.2016.12.013","volume":"104","author":"S Lakhundi","year":"2017","unstructured":"Lakhundi S, Siddiqui R, Khan NA (2017) Pathogenesis of Microbial Keratitis. Microb Pathog 104:97\u2013109","journal-title":"Microb Pathog"},{"issue":"1","key":"4268_CR43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","volume":"103","author":"AC Leenders","year":"1998","unstructured":"Leenders AC et al (1998) Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 103(1):205\u2013212","journal-title":"Br J Haematol"},{"key":"4268_CR44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00253-005-1955-9","volume":"68","author":"A Lemke","year":"2005","unstructured":"Lemke A, Kiderlen A, Kayser O (2005) Amphotericin b. Appl Microbiol Biotechnol 68:151\u2013162","journal-title":"Appl Microbiol Biotechnol"},{"issue":"Supplement_2","key":"4268_CR45","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/jac\/dkac352","volume":"77","author":"J Maertens","year":"2022","unstructured":"Maertens J et al (2022) Liposomal amphotericin B\u2014the present. J Antimicrob Chemother 77(Supplement_2):ii11\u2013ii20","journal-title":"J Antimicrob Chemother"},{"key":"4268_CR46","unstructured":"Maw PD (2019) Development of cyclodextrin-based pickering nanoemulsion containing amphotericin b for treatment of fungal keratitis"},{"key":"4268_CR47","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/978-3-319-46718-4_26","volume":"1","author":"M McCarthy","year":"2017","unstructured":"McCarthy M, O\u2019Shaughnessy EM, Walsh TJ (2017) Amphotericin B: polyene resistance mechanisms. Antimicrob Drug Resist: Mech Drug Resist 1:387\u2013395","journal-title":"Antimicrob Drug Resist: Mech Drug Resist"},{"issue":"7","key":"4268_CR48","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3109\/17435390.2016.1153165","volume":"10","author":"NK Mehra","year":"2016","unstructured":"Mehra NK et al (2016) Safety and toxicity of nanomaterials for ocular drug delivery applications. Nanotoxicology 10(7):836\u2013860","journal-title":"Nanotoxicology"},{"issue":"9","key":"4268_CR49","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2174\/1567201818666210316111941","volume":"18","author":"TZ Mehrizi","year":"2021","unstructured":"Mehrizi TZ et al (2021) A review study about the effect of chitosan nanocarrier on improving the efficacy of amphotericin B in the treatment of Leishmania from 2010 to 2020. Curr Drug Deliv 18(9):1234\u20131243","journal-title":"Curr Drug Deliv"},{"issue":"1\u20132","key":"4268_CR50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijpharm.2007.04.028","volume":"344","author":"K Morand","year":"2007","unstructured":"Morand K et al (2007) Liposomal amphotericin B eye drops to treat fungal keratitis: physico-chemical and formulation stability. Int J Pharm 344(1\u20132):150\u2013153","journal-title":"Int J Pharm"},{"issue":"2","key":"4268_CR51","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1021\/mp3005963","volume":"10","author":"PW Morrison","year":"2013","unstructured":"Morrison PW, Connon CJ, Khutoryanskiy VV (2013) Cyclodextrin-mediated enhancement of riboflavin solubility and corneal permeability. Mol Pharm 10(2):756\u2013762","journal-title":"Mol Pharm"},{"issue":"3","key":"4268_CR52","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.nano.2008.03.007","volume":"4","author":"M Nahar","year":"2008","unstructured":"Nahar M et al (2008) Development, characterization, and toxicity evaluation of amphotericin B\u2013loaded gelatin nanoparticles. Nanomedicine: Nanotechnol Biol Med 4(3):252\u2013261","journal-title":"Nanomedicine: Nanotechnol Biol Med"},{"issue":"1","key":"4268_CR53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3921\/joptom.2009.3","volume":"2","author":"R Navarro","year":"2009","unstructured":"Navarro R (2009) The optical design of the human eye: a critical review. J Optom 2(1):3\u201318","journal-title":"J Optom"},{"issue":"1","key":"4268_CR54","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/jbm.b.33356","volume":"104","author":"AC Parker","year":"2016","unstructured":"Parker AC et al (2016) Preliminary evaluation of local drug delivery of amphotericin B and in vivo degradation of chitosan and polyethylene glycol blended sponges. J Biomed Mater Res B Appl Biomater 104(1):78\u201387","journal-title":"J Biomed Mater Res B Appl Biomater"},{"issue":"24","key":"4268_CR55","doi-asserted-by":"crossref","first-page":"14327","DOI":"10.1073\/pnas.2332326100","volume":"100","author":"AJ Phillips","year":"2003","unstructured":"Phillips AJ, Sudbery I, Ramsdale M (2003) Apoptosis induced by environmental stresses and amphotericin B in Candida albicans. Proc Natl Acad Sci 100(24):14327\u201314332","journal-title":"Proc Natl Acad Sci"},{"issue":"647","key":"4268_CR56","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/pgmj.55.647.667","volume":"55","author":"A Polak","year":"1979","unstructured":"Polak A (1979) Pharmacokinetics of amphotericin B and flucytosine. Postgrad Med J 55(647):667\u2013670","journal-title":"Postgrad Med J"},{"issue":"1","key":"4268_CR57","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2007.11.008","volume":"15","author":"P Power","year":"2008","unstructured":"Power P et al (2008) Engineered synthesis of 7-oxo-and 15-deoxy-15-oxo-amphotericins: insights into structure-activity relationships in polyene antibiotics. Chem Biol 15(1):78\u201386","journal-title":"Chem Biol"},{"issue":"3","key":"4268_CR58","first-page":"597","volume":"8","author":"S Qiu","year":"2015","unstructured":"Qiu S et al (2015) Natamycin in the treatment of fungal keratitis: a systematic review and Meta-analysis. Int J Ophthalmol 8(3):597","journal-title":"Int J Ophthalmol"},{"issue":"11","key":"4268_CR59","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3390\/jof7110907","volume":"7","author":"N Raj","year":"2021","unstructured":"Raj N et al (2021) Recent perspectives in the management of fungal keratitis. J Fungi (Basel) 7(11):907","journal-title":"J Fungi (Basel)"},{"issue":"5","key":"4268_CR60","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/pharmaceutics14050989","volume":"14","author":"GS Ramos","year":"2022","unstructured":"Ramos GS et al (2022) Formulation of amphotericin B in PEGylated liposomes for improved treatment of cutaneous leishmaniasis by parenteral and oral routes. Pharmaceutics 14(5):989","journal-title":"Pharmaceutics"},{"issue":"11","key":"4268_CR61","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/jof10110762","volume":"10","author":"C Rapti","year":"2024","unstructured":"Rapti C et al (2024) Amphotericin B ocular films for fungal keratitis and a novel 3D-printed microfluidic ocular lens infection model. Journal of Fungi 10(11):762","journal-title":"Journal of Fungi"},{"key":"4268_CR62","unstructured":"Rege J (2014) The steroid metabolome and transcriptome of the human adrenal gland. Georgia Regents University"},{"issue":"5","key":"4268_CR63","doi-asserted-by":"crossref","first-page":"a019703","DOI":"10.1101\/cshperspect.a019703","volume":"4","author":"T Roemer","year":"2014","unstructured":"Roemer T, Krysan DJ (2014) Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med 4(5):a019703","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"4268_CR64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1439-0507.2012.02197.x","volume":"56","author":"SM Rudramurthy","year":"2013","unstructured":"Rudramurthy SM et al (2013) In vitro antifungal activity of Indian liposomal amphotericin B against clinical isolates of emerging species of yeast and moulds, and its comparison with amphotericin B deoxycholate, voriconazole, itraconazole and fluconazole. Mycoses 56(1):39\u201346","journal-title":"Mycoses"},{"issue":"2","key":"4268_CR65","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2165\/00002018-199005020-00003","volume":"5","author":"R Sabra","year":"1990","unstructured":"Sabra R, Branch RA (1990) Amphotericin B nephrotoxicity. Drug Saf 5(2):94\u2013108","journal-title":"Drug Saf"},{"key":"4268_CR66","doi-asserted-by":"crossref","first-page":"103721","DOI":"10.1016\/j.jddst.2022.103721","volume":"75","author":"SN Sanap","year":"2022","unstructured":"Sanap SN et al (2022) A recent update on therapeutic potential of vesicular system against fungal keratitis. J Drug Deliv Sci Technol 75:103721","journal-title":"J Drug Deliv Sci Technol"},{"issue":"3","key":"4268_CR67","first-page":"257","volume":"3","author":"Y Shao","year":"2010","unstructured":"Shao Y et al (2010) Therapeutic efficacy of intracameral amphotericin B injection for 60 patients with keratomycosis. Int J Ophthalmol 3(3):257\u2013260","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"4268_CR68","doi-asserted-by":"crossref","first-page":"2300462","DOI":"10.1002\/biot.202300462","volume":"19","author":"N Sharifi","year":"2024","unstructured":"Sharifi N et al (2024) Developing nanosize carrier systems for Amphotericin-B: a review on the biomedical application of nanoparticles for the treatment of leishmaniasis and fungal infections. Biotechnol J 19(1):2300462","journal-title":"Biotechnol J"},{"key":"4268_CR69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jtos.2021.12.001","volume":"24","author":"N Sharma","year":"2022","unstructured":"Sharma N et al (2022) Fungal keratitis: a review of clinical presentations, treatment strategies and outcomes. Ocul Surf 24:22\u201330","journal-title":"Ocul Surf"},{"issue":"1","key":"4268_CR70","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/infdis\/154.1.76","volume":"154","author":"ML Sokol-Anderson","year":"1986","unstructured":"Sokol-Anderson ML, Brajtburg J, Medoff G (1986) Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis 154(1):76\u201383","journal-title":"J Infect Dis"},{"issue":"3","key":"4268_CR71","first-page":"895","volume":"52","author":"WJ Steinbach","year":"2005","unstructured":"Steinbach WJ (2005) Antifungal agents in children. Pediatr Clin 52(3):895\u2013915","journal-title":"Pediatr Clin"},{"key":"4268_CR72","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.actbio.2021.10.047","volume":"138","author":"X Sun","year":"2022","unstructured":"Sun X et al (2022) Mucoadhesive phenylboronic acid conjugated chitosan oligosaccharide-vitamin E copolymer for topical ocular delivery of voriconazole: synthesis, in vitro\/vivo evaluation, and mechanism. Acta Biomater 138:193\u2013207","journal-title":"Acta Biomater"},{"key":"4268_CR73","unstructured":"Suwarna S et al (2021) Fungal keratitis: recent advances in diagnosis and treatment. In: Alejandro R-G, Julio CH-C (eds.) Infectious Eye Diseases, IntechOpen, Rijeka, p Ch. 3"},{"issue":"8","key":"4268_CR74","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1128\/AAC.00270-13","volume":"57","author":"AN Tevyashova","year":"2013","unstructured":"Tevyashova AN et al (2013) Structure-antifungal activity relationships of polyene antibiotics of the amphotericin B group. Antimicrob Agents Chemother 57(8):3815\u20133822","journal-title":"Antimicrob Agents Chemother"},{"issue":"1\u20132","key":"4268_CR75","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijpharm.2006.08.013","volume":"329","author":"W Tiyaboonchai","year":"2007","unstructured":"Tiyaboonchai W, Limpeanchob N (2007) Formulation and characterization of amphotericin B\u2013chitosan\u2013dextran sulfate nanoparticles. Int J Pharm 329(1\u20132):142\u2013149","journal-title":"Int J Pharm"},{"key":"4268_CR76","doi-asserted-by":"crossref","first-page":"120640","DOI":"10.1016\/j.ijpharm.2021.120640","volume":"602","author":"D Urimi","year":"2021","unstructured":"Urimi D et al (2021) Formulation development and upscaling of lipid nanocapsules as a drug delivery system for a novel cyclic GMP analogue intended for retinal drug delivery. Int J Pharm 602:120640","journal-title":"Int J Pharm"},{"issue":"8","key":"4268_CR77","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.apsb.2021.04.010","volume":"11","author":"X Wang","year":"2021","unstructured":"Wang X et al (2021) Delivery strategies of amphotericin B for invasive fungal infections. Acta Pharmaceutica Sinica B 11(8):2585\u20132604","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"8","key":"4268_CR78","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/bjo.81.8.622","volume":"81","author":"JP Whitcher","year":"1997","unstructured":"Whitcher JP, Srinivasan M (1997) Corneal ulceration in the developing world\u2014a silent epidemic. Br J Ophthalmol 81(8):622\u2013623","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"4268_CR79","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/514672","volume":"27","author":"MH White","year":"1998","unstructured":"White MH et al (1998) Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 27(2):296\u2013302","journal-title":"Clin Infect Dis"},{"issue":"7","key":"4268_CR80","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.18240\/ijo.2021.07.20","volume":"14","author":"R-B Yang","year":"2021","unstructured":"Yang R-B et al (2021) Immunologic mechanism of fungal keratitis. Int J Ophthalmol 14(7):1100","journal-title":"Int J Ophthalmol"},{"issue":"11","key":"4268_CR81","doi-asserted-by":"crossref","first-page":"18729","DOI":"10.1021\/acsnano.2c07444","volume":"16","author":"Y Ye","year":"2022","unstructured":"Ye Y et al (2022) Cell wall destruction and internal cascade synergistic antifungal strategy for fungal keratitis. ACS Nano 16(11):18729\u201318745","journal-title":"ACS Nano"},{"issue":"3","key":"4268_CR82","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2174\/1381612822666161027103640","volume":"23","author":"S Zaioncz","year":"2017","unstructured":"Zaioncz S, Maissar Khalil N, Mara Mainardes R (2017) Exploring the role of nanoparticles in amphotericin B delivery. Curr Pharm Des 23(3):509\u2013521","journal-title":"Curr Pharm Des"},{"issue":"1","key":"4268_CR83","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/11206721231174653","volume":"34","author":"F Zhang","year":"2024","unstructured":"Zhang F, Zhang J, Zhang W (2024a) Recent advances in nanotechnology for the treatment of fungal keratitis. Eur J Ophthalmol 34(1):18\u201329","journal-title":"Eur J Ophthalmol"},{"issue":"4\u20136","key":"4268_CR84","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/bdd.2406","volume":"45","author":"X Zhang","year":"2024","unstructured":"Zhang X et al (2024b) Application of physiologically based pharmacokinetic model to compare the biodistribution of liposomal amphotericin B with conventional amphotericin B deoxycholate in humans. Biopharm Drug Dispos 45(4\u20136):208\u2013219","journal-title":"Biopharm Drug Dispos"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04268-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04268-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04268-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T11:14:53Z","timestamp":1761304493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04268-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":84,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4268"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04268-8","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"11 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The literature review was conducted, and the following keywords were used in the search: amphotericin b, nanocarriers, pathophysiology, etiology, corneal ulcer, fungal keratitis, infection, managemental strategy, structural properties. The databases searched included PubMed\/MEDLINE, Web of Science, Google Scholar, and Science Direct. A total of 153 articles were screened, and 85 were selected based on the inclusion and exclusion criteria. The inclusion criteria involved studies focusing on fungal keratitis management through amphotericin B and its nanocarriers.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}